Table 1.

Baseline characteristics and outcomes of ABS patients with (study cohort) and without coronary vasomotor function testing.

Variable	Study cohort (n=10)	Controls (n=218)	p-value
Clinical characteristics
Age (years)	61 (48–75)	71 (62–80)	0.03
Female	10 (100)	206 (94.5)	0.45
Hypertension	6 (60)	156 (72.2)	0.40
Diabetes mellitus	1 (10)	29 (13.4)	0.75
Hyperlipidaemia	5 (50)	93 (43.1)	0.66
Smoking	3 (30)	61 (29.5)	0.97
ECG findings
ST-segment elevation	2 (20)	98 (45.8)	0.11
Deep T-wave inversion	4 (40)	100 (47)	0.88
Maximum corrected QT interval	528 (431–597)	494 (463–591)	0.75
Biomarkers
Peak troponin (ng/ml)	1.13 (0.26–1.52)	0.45 (0.15–0.84)	0.23
Peak CK-MB (ng/ml)	17.4 (7.4–34.1)	11.6 (7.9–20.1)	0.43
Echocardiographic findings
Ejection fraction (%)	35 (25–55)	35 (30–45)	0.58
Wall motion score index	2.32 (1.83–2.43)	1.94 (1.69–2.25)	0.15
Right ventricular systolic pressure (mmHg)	48 (31–52)	43 (33–51)	0.73
Mitral regurgitation present	3 (75)	120 (64)	0.65
Clinical course
Length of hospitalization (days)	8 (3.5–20)	5 (3–8)	0.64
Days in the intensive care unit	1 (1–2)	1 (1–3)	0.99
Acute heart failure	3 (60)	76 (35.4)	0.24
Intra-aortic balloon pump	1 (20)	17 (8)	0.33
Mechanical ventilation	2 (40)	43 (20)	0.28

Values are median (interquartile range) or n (%).

CK, creatinine kinase.